IGF-I mediated survival pathways in normal and malignant cells.
about
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaInsulin-like growth factor-I for the treatment of amyotrophic lateral sclerosisHwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenograftsA review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patientsYAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferationParafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult miceInsulin signaling regulates mitochondrial function in pancreatic beta-cellsR1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyA phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapyNorthwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachThe insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.SirT1 enhances survival of human osteoarthritic chondrocytes by repressing protein tyrosine phosphatase 1B and activating the insulin-like growth factor receptor pathway.Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancyThe human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop.Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line.Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell LineageInitial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner.High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapyRemodeling the cardiac transcriptional landscape with diet.Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study.A systems-level interrogation identifies regulators of Drosophila blood cell number and survival.Convergence and divergence of genetic and modular networks between diabetes and breast cancer.Cell and molecular mechanisms of insulin-induced angiogenesis.Inhibitors of metabolism rescue cell death in Huntington's disease models.Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma cell death via a process involving AKT and Bcl-x(L).Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.Oxidative stress due to radiation in CD34(+) hematopoietic progenitor cells: protection by IGF-1Effect of insulin-like growth factor blockade on hyperoxia-induced lung injury.Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.Inducing apoptosis of human colon cancer cells by an IGF-I D domain analogue peptide.Predicted mechanisms of resistance to mTOR inhibitors.Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.Polymorphisms of Insulin-Like Growth Factor 1 Pathway Genes and Breast Cancer Risk.HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
P2860
Q24607285-CFA986F9-5F33-4E56-8073-09CB1A08B2E4Q24630353-4103B101-C6A8-4FBB-B3F7-52C735F8DF67Q27334603-61D70C28-DF38-4F59-BD2D-7ACF223F6F33Q28076622-800D0CA1-C4E1-4DDD-9DE4-C649A659360DQ28507494-957EB614-E2DA-4B0F-9A2D-83B7E05AC4C1Q28592704-23CF11A9-1FDA-4CD9-8ADB-C28E745F4691Q30945275-E5684579-09CA-473C-B1D7-3E60F8AD7AD6Q33397796-2EBB68A0-A535-4BA3-A9D4-7A3A833AA5D4Q33418329-D371FA78-F683-4D5F-9F6F-B78FC7A29E4DQ33710179-9BF1EA45-AEBA-460B-8A28-BF4805B13C76Q33843662-F2FB9404-B0AE-480B-B94F-547345ABE8ACQ33925323-B94AF744-1BD7-4285-953B-58A10C097FA4Q34059707-051A623C-62BE-49CE-9A17-AF4CD736B65AQ34072652-0D5D5F56-2EB6-4430-9A7A-B6494F413EA3Q34104101-4D196B9A-A760-4C6A-8544-56B1D5C11D81Q34380167-3925EC24-71B7-4940-A69C-325A4B2C4A3DQ34414710-A165B5C0-3ACE-4B43-BE53-C84272C1666EQ34414730-8E406374-4B8E-413A-A245-CC69B35C2D4EQ34504974-CDC82290-B0B0-46D4-8C31-EB4091679A66Q34661631-FAE40760-EA7E-4A3C-BD6E-C50AF9412964Q34683782-25F4867C-F701-48C3-A69A-67810CB56CAAQ34698741-119C8457-E402-4E77-A7AF-21C9436220BFQ34774874-98CC9D7E-5CF5-4AD0-9C9D-F1DBBDD0BA3DQ35062526-83877CBB-9A12-41BC-AC84-A1090FB96010Q35135708-248C8C0D-3182-4BBE-98EB-4C908BADDE48Q35154724-E7E50734-76AF-464B-869F-497E4B698342Q35571951-8D064840-CEB9-43D1-A2C7-25EEA764944BQ35889110-B11BD070-4C27-4A38-8CE4-2AB5CDB72C77Q35971716-B450E7FE-A1F8-4FF5-A568-5AE2E89D21B1Q36076295-946D1DB9-0EB1-479D-8B8A-D1DF7EBC49F7Q36170917-8263D153-432B-4EB7-895E-26CC9C17C3A6Q36197789-0CC19E23-FF3E-4C91-9C05-8F97A53DC02EQ36370176-9488C478-8A15-4735-8447-8B7C002BC296Q36456430-65B6497F-673A-4DA5-80CE-E74EB3B3F268Q36512572-68211C3C-614A-4B48-940C-7BF3DDE5CEBDQ36585744-2ED2F2B4-864E-45D8-89FE-02EDA3CE640FQ36736740-ED004704-EC3E-4941-903D-9A2168281BBDQ36924505-120DFAC7-9076-4F63-9A28-7E82D54F26A2Q36978703-D031BA12-29C8-4719-B13C-1DE9B8D6F079Q37038068-9D58742D-5490-4130-BE57-6CDD87449913
P2860
IGF-I mediated survival pathways in normal and malignant cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
IGF-I mediated survival pathways in normal and malignant cells.
@ast
IGF-I mediated survival pathways in normal and malignant cells.
@en
type
label
IGF-I mediated survival pathways in normal and malignant cells.
@ast
IGF-I mediated survival pathways in normal and malignant cells.
@en
prefLabel
IGF-I mediated survival pathways in normal and malignant cells.
@ast
IGF-I mediated survival pathways in normal and malignant cells.
@en
P1476
IGF-I mediated survival pathways in normal and malignant cells.
@en
P2093
Peter J Houghton
Raushan T Kurmasheva
P356
10.1016/J.BBCAN.2006.05.003
P407
P577
2006-06-07T00:00:00Z